Healthcare

Newswire

[ March 27, 2024 ] Snow Lake (NASDAQ: LTIM) Initiates 2024 Exploration Program at Engo Valley Uranium Project Mining & Metals
[ February 26, 2024 ] Snow Lake (NASDAQ: LITM)Transformational Acquisition of the Highly Prospective Engo Valley Uranium Project, Namibia Mining & Metals
[ February 13, 2024 ] Snow Lake (NASDAQ: LITM) Expands Its Lithium Portfolio with Mineral Claims near Kenora, Ontario Mining & Metals
[ January 16, 2024 ] Appia (OTC: APAAF) Reports 92,758 ppm (9.3%) TREO, 13,798 ppm MREO (1.38%) and 2,241 (.24%) ppm HREO over 2m Within the Total Weighted Average of 38,655 ppm (3.87%) TREO, 6,869 ppm (.69%) MREO, and 1,380 ppm (.14%) HREO Across 24m (EOH) Following the Reanalysis of Over-Limit Assay Results from PCH-RC-063 at the PCH Ionic Adsorption Clay Project in Goias, Brazil Mining & Metals
[ January 15, 2024 ] Appia (OTC: APAAF) Announces Significant Geochemical Critical REE Assay Results at Alces Lake Project, Saskatchewan, Canada Mining & Metals
[ January 12, 2024 ] Appia Receives Approval for 12 Additional Claim Blocks at Its PCH Rare Earths Ionic Adsorption Clay Project, Goias, Brazil Mining & Metals
[ January 12, 2024 ] Snow Lake Lithium (NASDAQ: LITM) CEO Update to Shareholders Mining & Metals
[ December 21, 2023 ] Snow Lake (NASDAQ: LITM) Expands Its Lithium Portfolio with Mineral Claims Next to the Tanco Mine Mining & Metals
[ December 18, 2023 ] Appia (OTC: APAAF) Announces Non-Brokered Flow-Through Private Placement Mining & Metals
[ December 13, 2023 ] Appia (OTC: APAAF) Announces Scandium and Cobalt Discovery at Its New Buriti Target at the PCH Project, Brazil; Reverse Circulation Drill Hole Returns 24 Metres of Mineralization Averaging 128 ppm Scandium Oxide, 272 ppm Total Cobalt Oxides and 2,106 ppm Total Rare Earth Oxides from Surface Mining & Metals

Healthcare

InnerScope Hearing Technologies Inc. & Erchonia Corporation to Conduct FDA Clinical Trial for the Treatment of Tinnitus

November 8, 2018 admin Comments Off

InnerScope and Erchonia have entered into Joint Development & Exclusive Distribution Agreements and intend to obtain a 510k FDA-Clearance via clinical trial to study the effect on using Erchonia’s Low-Level Laser Therapy Technology for […]

Innerscope Hearing Technologies (OTC: INND) Consolidation opportunity in $4 billion US hearing aid market

November 7, 2018 admin Comments Off

Innerscope Hearing Technologies (OTC: INND) CEO Interview with Matthew Moore, discussing consolidation opportunity in $4billion US hearing aid market, Walmart online distribution […]

Tetra Bio-Pharma (TSX: TBP) (OTC: TBPMF) CEO Guy Chamberland, Ph.D., discusses cannabinoid-based drug pipeline.

October 17, 2018 admin Comments Off

Tetra Bio-Pharma (TSX: TBP) (OTC: TBPMF) CEO Guy Chamberland, Ph.D., shares update on Tetra’s Cannabinoid-based drug pipeline as opioid alternative. Investor Presentation Deck

Healthcare

Pulmatrix (NASDAQ: PULM) Investor Presentation

October 8, 2018 admin Comments Off

Pulmatrix (NASDAQ: PULM) Investor Presentation 9/5/2018

The $TRILLION Opportunity in CRISPR & DNA Sequencing Technologies

July 16, 2018 admin Comments Off

Cathie Wood, of ARK Genomic Revolution ETF(NYSE: ARKG) explains the multi-trillion dollar opportunity in the Genomics Revolution: CAR-T, CRISPR, and DNA Sequencing

Celyad (NASDAQ: CYAD) CEO Christian Homsy shares his vision for universal CAR-T

March 19, 2018 admin Comments Off

Celyad (NASDAQ: CYAD) CEO Christian Homsy shares his vision for universal CAR-T

How to Trade Biotech and Pharmaceutical Stocks

March 11, 2018 admin Comments Off

How to Trade Biotech and Pharmaceutical Stocks Profiting from the FDA approval cycle

Exelixis (NASDAQ: EXEL) CEO Michael Morrissey gives an update on cabozantinib

March 10, 2018 admin Comments Off

Exelixis (NASDAQ: EXEL) CEO Michael Morrissey gives an update on cabozantinib

Picking Biotech Stocks in the Trump Era

February 7, 2018 admin Comments Off

Acura Pharmaceuticals Announces Successful Results from Study AP-LTX-301

January 10, 2018 admin Comments Off

PALATINE, Ill., Jan 08, 2018 -Acura Pharmaceuticals, Inc. (OTC QB: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that topline results from clinical study AP-LTX-301 (Study 301) for its LIMITx(TM) excess oral […]